1-7 of 7
Mark A. Deeg
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Erratum. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39: 1241–1249

Christof M. Kazda, Ying Ding, Ronan P. Kelly, Parag Garhyan, Chunxue Shi, Chay Ngee Lim, Haoda Fu, David E. Watson, Andrew J. Lewin, William H. Landschulz, Mark A. Deeg, David E. Moller, Thomas A. Hardy
Journal: Diabetes Care
Diabetes Care 2017;40(6):808
https://doi.org/10.2337/dc17-er06
Published: 18 April 2017
View articletitled, Erratum. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39: 1241–1249
Open the PDF for Erratum. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39: 1241–1249 in another window
Journal Articles

Response to Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241–1249

Christof M. Kazda, Ying Ding, Ronan P. Kelly, Parag Garhyan, Chunxue Shi, Chay Ngee Lim, Haoda Fu, David E. Watson, Andrew J. Lewin, William H. Landschulz, Mark A. Deeg, David E. Moller, Thomas A. Hardy
Journal: Diabetes Care
Diabetes Care 2016;39(11):e199–e200
https://doi.org/10.2337/dci16-0030
Published: 11 October 2016
View articletitled, Response to Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241–1249
Open the PDF for Response to Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241–1249 in another window
Journal Articles

Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies

Christof M. Kazda, Ying Ding, Ronan P. Kelly, Parag Garhyan, Chunxue Shi, Chay Ngee Lim, Haoda Fu, David E. Watson, Andrew J. Lewin, William H. Landschulz, Mark A. Deeg, David E. Moller, Thomas A. Hardy
Journal: Diabetes Care
Diabetes Care 2016;39(7):1241–1249
https://doi.org/10.2337/dc15-1643
Published: 17 December 2015
View articletitled, Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies
Open the PDF for Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies in another window
Includes: Supplementary data
Journal Articles

Pioglitazone and Rosiglitazone Have Different Effects on Serum Lipoprotein Particle Concentrations and Sizes in Patients With Type 2 Diabetes and Dyslipidemia

Mark A. Deeg, MD, John B. Buse, MD, Ronald B. Goldberg, MD, David M. Kendall, MD, Anthony J. Zagar, MS, Scott J. Jacober, DO, Mehmood A. Khan, MD, Alfonzo T. Perez, MD, Meng H. Tan, MD, on behalf of the GLAI Study Investigators
Journal: Diabetes Care
Diabetes Care 2007;30(10):2458–2464
https://doi.org/10.2337/dc06-1903
Published: 01 October 2007
View articletitled, Pioglitazone and Rosiglitazone Have Different Effects on Serum Lipoprotein Particle Concentrations and Sizes in Patients With Type 2 Diabetes and Dyslipidemia
Open the PDF for Pioglitazone and Rosiglitazone Have Different Effects on Serum Lipoprotein Particle Concentrations and Sizes in Patients With Type 2 Diabetes and Dyslipidemia in another window
Journal Articles

A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia: Response to Bell and Brunzell

Ronald B. Goldberg, MD, David M. Kendall, MD, Mark A. Deeg, MD, PHD, John B. Buse, MD, PHD, Anthony J. Zagar, MS, Jane A. Pinaire, PHD, Meng H. Tan, MD, Mehmood A. Khan, MD, Alfonso T. Perez, MD, Scott J. Jacober, DO, for the GLAI Study Investigators
Journal: Diabetes Care
Diabetes Care 2005;28(12):2985–2986
https://doi.org/10.2337/diacare.28.12.2985
Published: 01 December 2005
View articletitled, A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia: Response to Bell and Brunzell
Open the PDF for A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia: Response to Bell and Brunzell in another window
Journal Articles

A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia

Ronald B. Goldberg, MD, David M. Kendall, MD, Mark A. Deeg, MD, PHD, John B. Buse, MD, PHD, Anthony J. Zagar, MS, Jane A. Pinaire, PHD, Meng H. Tan, MD, Mehmood A. Khan, MD, Alfonso T. Perez, MD, Scott J. Jacober, DO, for the GLAI Study Investigators
Journal: Diabetes Care
Diabetes Care 2005;28(7):1547–1554
https://doi.org/10.2337/diacare.28.7.1547
Published: 01 July 2005
View articletitled, A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia
Open the PDF for A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia in another window
Journal Articles

Simvastatin, Fenofibrate, and Rhabdomyolysis

Sindhu S. Jacob, MD, Sony Jacob, MD, Craig Williams, PHARMD, Mark A. Deeg, MD, PHD
Journal: Diabetes Care
Diabetes Care 2005;28(5):1258
https://doi.org/10.2337/diacare.28.5.1258
Published: 01 May 2005
View articletitled, Simvastatin, Fenofibrate, and Rhabdomyolysis
Open the PDF for Simvastatin, Fenofibrate, and Rhabdomyolysis in another window